Biologics' switching: new insights toward establishing practice norms.
作者信息
Mahagna Hussein, Ben-Horin Shomron
机构信息
Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
出版信息
United European Gastroenterol J. 2019 Jul;7(6):733-734. doi: 10.1177/2050640619851683. Epub 2019 Jun 21.
Abstract
摘要
相似文献
1
Biologics' switching: new insights toward establishing practice norms.生物制剂的转换：建立实践规范的新见解。
United European Gastroenterol J. 2019 Jul;7(6):733-734. doi: 10.1177/2050640619851683. Epub 2019 Jun 21.
2
Switching biologics used in inflammatory bowel diseases: how to deal with in practice?炎症性肠病中生物制剂的转换：如何在实践中应对？
Curr Opin Pharmacol. 2020 Dec;55:82-89. doi: 10.1016/j.coph.2020.10.003. Epub 2020 Nov 6.
3
Precision Medicine in Inflammatory Bowel Diseases.炎症性肠病精准医学。
Clin Pharmacol Ther. 2017 Oct;102(4):623-632. doi: 10.1002/cpt.793. Epub 2017 Aug 24.
4
Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease.炎症性肠病中生物制剂与生物类似药的转换
Clin Gastroenterol Hepatol. 2019 Apr;17(5):818-823. doi: 10.1016/j.cgh.2018.08.064. Epub 2018 Sep 7.
5
Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use.生物制剂时代钙调神经磷酸酶抑制剂在炎症性肠病中的作用：何时及如何使用。
Inflamm Bowel Dis. 2014 Nov;20(11):2151-6. doi: 10.1097/MIB.0000000000000130.
6
Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases.2012 - 2014年波兰炎症性肠病的患病率及药物治疗情况：基于全国数据库的分析
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):456-464. doi: 10.1097/MEG.0000000000001047.
7
Insights on the use of biosimilars in the treatment of inflammatory bowel disease.生物类似药在炎症性肠病治疗中的应用见解。
World J Gastroenterol. 2017 Mar 21;23(11):1932-1943. doi: 10.3748/wjg.v23.i11.1932.
8
The role of biologics in the treatment of patients with inflammatory bowel disease.生物制剂在炎症性肠病患者治疗中的作用。
Br J Hosp Med (Lond). 2018 Dec 2;79(12):686-693. doi: 10.12968/hmed.2018.79.12.686.
9
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?在炎症性肠病中使用和理解抗 TNF 药物的治疗药物监测方面存在广泛差异：这是一门不精确的科学吗？
Expert Opin Biol Ther. 2018 Dec;18(12):1271-1279. doi: 10.1080/14712598.2018.1537367. Epub 2018 Oct 24.
10
Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement.香港炎症性肠病生物制剂的使用：共识声明。
Hong Kong Med J. 2013 Feb;19(1):61-8.
引用本文的文献
1
Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases.伊朗成人炎症性肠病生物制剂和小分子药物药物治疗共识指南。
Middle East J Dig Dis. 2023 Apr;15(2):83-106. doi: 10.34172/mejdd.2023.327. Epub 2023 Apr 30.
2
Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?黏膜 TNF 转录本是否可以作为生物标志物候选物帮助优化溃疡性结肠炎患者的抗 TNF 生物治疗？
Front Immunol. 2022 May 19;13:881112. doi: 10.3389/fimmu.2022.881112. eCollection 2022.
本文引用的文献
1
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.一线英夫利昔单抗对炎症性肠病二线维得利珠单抗药代动力学的影响。
United European Gastroenterol J. 2019 Jul;7(6):750-758. doi: 10.1177/2050640619841538. Epub 2019 Mar 24.
2
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.在同时接受抗肿瘤坏死因子治疗的患者中，vedolizumab 的安全性、疗效和药代动力学。
Aliment Pharmacol Ther. 2018 Apr;47(8):1117-1125. doi: 10.1111/apt.14567. Epub 2018 Feb 15.
3
Vedolizumab as induction and maintenance therapy for Crohn's disease.维得利珠单抗作为克罗恩病的诱导缓解和维持治疗药物。
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
4
Vedolizumab as induction and maintenance therapy for ulcerative colitis.维得利珠单抗用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.
5
Infliximab, azathioprine, or combination therapy for Crohn's disease.英夫利昔单抗、硫唑嘌呤或联合治疗克罗恩病。
N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.
6
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.在接受抗肿瘤坏死因子治疗后进行洗脱或直接换用阿巴西普的类风湿关节炎患者中阿巴西普的6个月安全性和疗效：ARRIVE试验
Ann Rheum Dis. 2009 Nov;68(11):1708-14. doi: 10.1136/ard.2008.099218. Epub 2008 Dec 15.
7
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.对于在接受英夫利昔单抗治疗时未缓解的克罗恩病患者，同时使用那他珠单抗治疗的安全性和耐受性。
Inflamm Bowel Dis. 2007 Jan;13(1):2-11. doi: 10.1002/ibd.20014.
Zotero 插件